239 related articles for article (PubMed ID: 37858626)
21. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.
Li Y; Zhou W; Yang L; You R
Pharmacol Res; 2020 Jul; 157():104833. PubMed ID: 32302706
[TBL] [Abstract][Full Text] [Related]
22. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
23. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
Miura Y; Ohkubo H; Nakano A; Bourke JE; Kanazawa S
Front Immunol; 2022; 13():1028613. PubMed ID: 36405683
[TBL] [Abstract][Full Text] [Related]
24. Prediction of repurposed drugs for treating lung injury in COVID-19.
He B; Garmire L
F1000Res; 2020; 9():609. PubMed ID: 32934806
[No Abstract] [Full Text] [Related]
25. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
26. ACE2 mouse models: a toolbox for cardiovascular and pulmonary research.
Jia H; Yue X; Lazartigues E
Nat Commun; 2020 Oct; 11(1):5165. PubMed ID: 33057007
[TBL] [Abstract][Full Text] [Related]
27. Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2.
Barker H; Parkkila S
PLoS One; 2020; 15(10):e0240647. PubMed ID: 33112891
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.
Jia H
Shock; 2016 Sep; 46(3):239-48. PubMed ID: 27082314
[TBL] [Abstract][Full Text] [Related]
29. Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs.
Singh V; Beer A; Kraus A; Mang F; Zhang X; Xue J; Hagemann N; Hermann DM; Gunzer M
Brain Behav Immun; 2021 May; 94():458-462. PubMed ID: 33621620
[TBL] [Abstract][Full Text] [Related]
30. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
31. Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.
Hrenak J; Simko F
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126657
[TBL] [Abstract][Full Text] [Related]
32. USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice.
Dang F; Bai L; Dong J; Hu X; Wang J; Paulo JA; Xiong Y; Liang X; Sun Y; Chen Y; Guo M; Wang X; Huang Z; Inuzuka H; Chen L; Chu C; Liu J; Zhang T; Rezaeian AH; Liu J; Kaniskan HÜ; Zhong B; Zhang J; Letko M; Jin J; Lan K; Wei W
Sci Transl Med; 2023 Dec; 15(725):eadh7668. PubMed ID: 38055802
[TBL] [Abstract][Full Text] [Related]
33. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.
Wysocki J; Lores E; Ye M; Soler MJ; Batlle D
J Am Soc Nephrol; 2020 Sep; 31(9):1941-1943. PubMed ID: 32669323
[No Abstract] [Full Text] [Related]
34. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Kai H; Kai M
Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
[TBL] [Abstract][Full Text] [Related]
35. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
Zemlin AE; Wiese OJ
Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
Gemmati D; Bramanti B; Serino ML; Secchiero P; Zauli G; Tisato V
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32423094
[TBL] [Abstract][Full Text] [Related]
37. ACE2 and COVID-19 and the resulting ARDS.
Zhang X; Li S; Niu S
Postgrad Med J; 2020 Jul; 96(1137):403-407. PubMed ID: 32522846
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
Roshanravan N; Ghaffari S; Hedayati M
Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
[TBL] [Abstract][Full Text] [Related]
39. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.
Rao S; Lau A; So HC
Diabetes Care; 2020 Jul; 43(7):1416-1426. PubMed ID: 32430459
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.
Qiu Y; Shil PK; Zhu P; Yang H; Verma A; Lei B; Li Q
Invest Ophthalmol Vis Sci; 2014 May; 55(6):3809-18. PubMed ID: 24854854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
